INTRODUCTION
Mastalgia is one of the commonest symptoms in patients attending a breast clinic throughout the world and it is estimated that approximately 60-70% of women experience breast pain at some time of their life. However, there is no established cure for this common problem. Many drugs have been used with varying response, like Tamoxifen, Danazol, oil of evening primrose, topical analgesics and much recently, at least in India, a very commonly used, cheap oral contraceptive pill, Centchroman (distributed as 'Saheli'). Pharmacologically, Centchroman is Ormeloxifene, a nonsteroidal selective oestrogen receptor modulator (SERM) used primarily as an oral contraceptive. In a study by Dhar et al, for Centchroman in mastalgia, they found a 100% relief after 12 weeks of treatment with this drug. 1 On the other hand, in a meta-analysis done by Srivastava et al, it was found that Tamoxifen is the most effective form of treatment of mastalgia when compared with bromocriptine, Danazol and oil of evening primrose. Centchroman was not included in this study. 2 Rathi et al, reported 88% pain relief after 12 weeks of initiation of therapy with Centchroman. 3 Tejwani et al, found Centchroman to be better than Tamoxifen in reducing breast pain using the Visual Analogue Scale (VAS) in a randomized trial. 4 This study however did not include danazol as another comparative index. This present study was done, to compare the three most commonly used drugs in the treatment of mastalgia, namely Centchroman, Tamoxifen and Danazol with a Placebo.
METHODS
This study was conducted at a tertiary care teaching hospital of Central India from August 2016 to September 2017. All consecutive patients with age more than 25 years and mastalgia for more than three months were inducted in the study. A detailed history and clinical examinations were done, followed by sonomammography or digital mammography. Patients were also sent for Gynaecological assessment and an ultrasound pelvis was done to rule out any pelvic pathology.
Patients with breast lump or pelvic pathology were excluded from the study. Also, patients planning to conceive in the next 6 months were excluded from the study. Patients willing to take part in the study were registered after taking a detail informed consent.
A total of 78 patients fulfilled the study criteria and were enrolled in the study.
The patients thus chosen were divided into four groups using randomization by sealed envelope technique, handed over by the OPD sister in charge. Group A received Centchroman 30 mg daily, group B received danazol 200 mg daily, group C received Tamoxifen 20 mg daily and group D received a placebo (Vit B complex multivitamin) for a period of 3 months each.
Patients were asked to keep a record of breast pain for this duration. The patients were asked to fill in the occurrence of pain on a day to day basis with severity of mastalgia assessed by Visual Analogue Scale.
All subjects were followed after one week and tolerance to the drug assessed. Subsequently patients were followed at 4 weeks, 12 weeks and 24 weeks of starting treatment and response to therapy assessed.
RESULTS
A total of 78 patients enrolled for the study. 5 patients did not turn up or refused to continue in the study. So, the final outcome was studied on 73 patients; 23 patients in group A, 17 in group B, 14 in group C and 19 in group D. There was no statistically significant difference in the four groups, with respect to age, parity and the menstrual cycles (Table 1) . (Table 3) .
Side effects as secondary outcome measure
Maximum side effects were seen in the Danazol group. Of the 17 patients in the Danazol group, 8 patients had some or other form of menstrual irregularity, in the form of scanty menses, delayed menses, hot flushes or menorrhagia.
In the Centchroman group, 4 patients had oligomenorrhea, while 2 had delayed periods.
Whereas in the Tamoxifen group, 4 patients had delayed periods and 2 complained of hot flushes. 
DISCUSSION
The problem of cyclical mastalgia is grossly underestimated despite a significant detrimental effect on quality of life. 5 In present study we compared the effect of Centchroman, Tamoxifen, Danazol and Placebo on cyclical mastalgia.
The median and mean ages in present study were 30 and 30.57 years, respectively. This correlates with the median age of 34 years for cyclical mastalgia in the study done by Davies et al. 6 In the first week, there was no effect on pain with any of the drugs relative to placebo. But after 4 weeks, Centchroman was the most effective, followed by Tamoxifen and Danazol with the Placebo being the least effective. After 12 weeks and 24 weeks of treatment, Centchroman and Tamoxifen were together most effective compared to Danazol and Placebo. This result of present is supported by Dhar et al, who also found Centchroman to be more effective than Danazol and evening primrose oil for pain relief. 7 On comparison between Centchroman and Danazol, the pain relief was significantly better with Centchroman only at the 24 th week of treatment. Though pain relief was comparable at 4 and 12 weeks, Centchroman is cheapest among the three drugs, has a better side effect profile in contrast to Danazol, and hence would be a better choice than Danazol.
On comparison between Centchroman and Tamoxifen, the difference in pain relief was not statistically significant at any time during the study. Even though the difference in pain relief was equivocal, Centchroman had a lesser mean VAS score in the study. Jain et al, also found Centchroman and Tamoxifen to be equally effective for pain relief in mastalgia. 8 On comparison between Tamoxifen and Danazol, statistically significant pain relief was seen after 24 weeks. The difference in pain relief was again equivocal after 4 or 12 weeks.
All the three drugs were found to be superior to a placebo for pain relief for the whole duration of present study.
Centchroman overall had the best pain relief with the lowest mean VAS scores throughout present study, even though it was not found to be statistically better than Tamoxifen. In the study conducted by Tejawani et al, on 39 patients and after 12 weeks of treatment with Centchroman, 89.7% were relieved of pain similarly.
Bansal V et al, studied effect of Centchroman on 203 patients and reported that after 12 weeks of treatment the mean VAS was similarly found to be 1.21. 9 In two separate studies Rathi et al, and Srivastava et al, reported more than 85% relief in pain after 12 weeks of treatment with Centchroman which supports present study. 3, 10 More multicentric studies with a larger sample size are required to validate Centchroman as a more effective drug over the now more traditionally used Tamoxifen.
CONCLUSION
Cyclical mastalgia is commonly encountered in the premenstrual phase in women most commonly 30-40 years of age. Mild cyclical mastalgia can be treated with reassurance and life style modifications. Moderate to severe mastalgia usually require drug treatment. Centchroman is non-steroidal and effective in providing relief with minimal side effects in cyclical mastalgia. Tamoxifen is another effective drug that can be used. Danazol is inferior to both Centchroman and Tamoxifen with regards to pain relief offered and anticipated side effects.
